Advertisement

Topics

Latest "Nitroglycerin lidocaine Placebo Cardiac Catheterization" News Stories

04:55 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "Nitroglycerin lidocaine Placebo Cardiac Catheterization" found in our extensive news archives from over 250 global news sources.

More Information about Nitroglycerin lidocaine Placebo Cardiac Catheterization on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Nitroglycerin lidocaine Placebo Cardiac Catheterization for you to read. Along with our medical data and news we also list Nitroglycerin lidocaine Placebo Cardiac Catheterization Clinical Trials, which are updated daily. BioPortfolio also has a large database of Nitroglycerin lidocaine Placebo Cardiac Catheterization Companies for you to search.

Showing "Nitroglycerin lidocaine Placebo Cardiac Catheterization" News Articles 1–25 of 2,400+

Thursday 21st February 2019

OBIO Opens 2019 Niagara Investment Summit, Connecting Canada’s Most Promising Innovations with Leading Global Investors

OBIO (Ontario Bioscience Innovation Organization) is proud to announce the opening of the 2019 Niagara Investment Summit in Niagara-on-the-Lake, Ontario, on February 21-22, 2019. The 2019 Niagara Investment Summit will feature over 30 of Canada’s most promising innovative health science companies meeting with more than 30 US and global investors...


Study of #macrophage heterogeneity in human #hearts reveals a subset of inflammatory macrophages that is associated with #cardiac dysfunction in patients with #heartfailure. https://go.nature.com/2GCErmT  #AmericanHeartMonth

Study of #macrophage heterogeneity in human #hearts reveals a subset of inflammatory macrophages that is associated with #cardiac dysfunction in patients with #heartfailure. https://go.nature.com/2GCErmT  #AmericanHeartMonth

Bavarian Nordic Announces Initiation of Phase 1/2a Clinical Trial of Therapeutic HPV Vaccine Regimen in Collaboration with Janssen

First commercial program under Bavarian Nordic and Janssen Vaccines & Prevention B.V. collaboration advancing into clinical trials A therapeutic vaccine may represent a novel approach for early treatment and interception of HPV-induced cancers COPENHAGEN, Denmark, February 21, 2019 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced that the first patient has been d...


This Month, SCMR Reminds Everyone that CMR Helps Get to the “Heart” of Cardiac Health

The Society for Cardiovascular Magnetic Resonance helps the public understand the value of using heart MRIs MOUNT ROYAL, N.J. (PRWEB) February 21, 2019 The Society for Cardiovascular Magnetic Resonance (SCMR), a Society dedicated to improving cardiovascular health by advancing the field of cardiovascular magnetic resonance (CMR), reminds the public not only that February is American Heart Month, ...

Nexus Pharmaceuticals Receives FDA Approval for Prochlorperazine Edisylate Injection, USP

Immediate Availability of AP Rated Prochlorperazine Edisylate 10mg/2mL Injection Nexus Pharmaceuticals announced today it has received U.S. Food and Drug Administration (FDA) approval for Prochlorperazine Edisylate Injection, USP in 10mg/2mL vial. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home...

BioSig announces successful first-in-human use of PURE EP system

The first commercial use of the System was completed at the Texas Cardiac Arrhythmia Institute (“TCAI”) in Austin, TX. The patient studies were conducted by Andrea Natale, M.D., The post BioSig announces successful first-in-human use of PURE EP system appeared first on Compelo Medical Devices.

Cardiovascular Performance Improvements including Lower Blood Pressure Discovered from Human Clinical Trial using Lexaria’s DehydraTECH(TM) Powered TurboCBD(TM) Capsules

Lexaria Bioscience Corp. (CSE:LXX, OTC:LXRP) (the "Company" or "Lexaria"), a drug delivery platform innovator, is pleased to announce additional significant findings upon completion of further data analyses from its 2018 randomized, placebo-controlled, double-blinded European human clinical study that evaluated TurboCBD(TM), the Company's proprietary, DehydraTECH(TM) powered, cannabidiol ("CBD") ...

Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure

THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019 /PRNewswire/ -- Amgen (NASDAQ: AMGN), Cytokinetics, Incorporated (NASDAQ: CYTK) and Servier today announced that METEORIC-HF (Multicenter Exercise Tolerance Evaluation of Omecamtiv Mecarbil Related to Increased Contractility in Heart Failure), the second Phase 3 clinical trial of omecamtiv mecarbil, a novel c...

First Patient Dosed in Complexa Phase 2 Trial of Lead Candidate CXA-10 to Treat Pulmonary Arterial Hypertension

Complexa Inc. today announced dosing of the first patient in PRIMEx, a Phase 2 clinical trial evaluating the safety and efficacy of two doses of the company’s lead candidate, CXA-10, to treat pulmonary arterial hypertension (PAH). PAH is a rare, progressive disease characterized by high blood pressure in the vessels that carry blood from the right side o...

Rivaroxaban Does Not Reduce VTE Incidence in High-Risk Cancer Patients

THURSDAY, Feb. 21, 2019 -- In high-risk ambulatory patients with cancer, the incidence of venous thromboembolism or death due to venous thromboembolism during 180 days is not significantly reduced for rivaroxaban compared with placebo, according to...

Wednesday 20th February 2019

Melanoma Research Alliance Welcomes FDA Approval of Pembrolizumab in Adjuvant Setting

The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food & Drug Administration (FDA) approval of Merck’s pembrolizumab (Keytruda®) in the adjuvant setting for melanoma patients with lymph node involvement following complete lymph node resection. Melanoma, the deadliest skin c...

Pembrolizumab Misses Primary Endpoints in HCC Trial

The combination of pembrolizumab plus best supportive care for the treatment of patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy did not improve progression-free or overall survival compared with placebo plus best supportive care alone, missing the coprimary endpoints of the KEYNOTE-240 trial.

Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

Cytokinetics (NASDAQ:CYTK) has announced the first subject has been dosed in a Phase 1 randomized, double-blind, placebo-controlled and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 594 in healthy patients. As quoted in the press release: AMG 594 is a cardiac troponin activator, discovered under a joint research program … Con...

Overlake and Wildflower Health Partner on O-Baby App to Guide Patients Along Pregnancy and New-Parent Journey

Expecting Mothers to Receive a Personalized Pregnancy Experience from Pre-natal Planning through Early Parenthood. BELLEVUE, Wash. (PRWEB) February 20, 2019 Overlake Medical Center and Wildflower Health announced today a digital partnership to improve pre-natal and maternal care for mothers and their families in the Puget Sound area. The partnership includes a free, mobile app called, O-Baby, whi...

HF With/Without Symptoms Tied to Higher Death Risk After Surgery (CME/CE)

(MedPage Today) -- Left ventricular function and other factors predict non-cardiac surgical outcomes in patients with heart failure

IV Acetaminophen May Combat Delirium After Cardiac Surgery

(MedPage Today) -- Older patients also had shorter ICU stays in single-center randomized trial

YPrime Inc. Becomes Stonehenge Growth Equity Partners’ Third Successful Exit in eClinical Software Market

Significant outside investment in YPrime illustrates winning strategy TAMPA, Fla. (PRWEB) February 20, 2019 Stonehenge Growth Equity Partners (SGEP) today announced a third successful exit in the clinical trials software market, as the SGEP portfolio company YPrime, Inc. received a significant growth investment led by Flexpoint Ford (Flexpoint), a Chicago-based private equity firm focused on the ...

$CYTK Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator $AMGN https://globenewswire.com/news-release/2019/02/20/1738428/0/en/Cytokinetics-Announces-Initiation-of-Phase-1-Clinical-Study-of-AMG-594-a-Cardiac-Troponin-A

$CYTK Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator $AMGN https://globenewswire.com/news-release/2019/02/20/1738428/0/en/Cytokinetics-Announces-Initiation-of-Phase-1-Clinical-Study-of-AMG-594-a-Cardiac-Troponin-Activator.html …

Affibody Completes Enrollment in Phase 2 Psoriasis Trial of ABY-035

Solna, Sweden, February 20, 2019. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a pipeline of innovative drug projects, today announced the completion of enrollment in the Company’s Phase 2 proof-of-concept study of ABY-035 for moderate-to-severe psoriasis (“AFFIRM-35”). “We are pleased that the Phase 2 AFFIRM-35 study wi...

Fast Company Names HeartFlow One of the World’s Most Innovative Companies

HeartFlow Earns a Top Position in Artificial Intelligence for 2019 HeartFlow, Inc., a medical technology company uniquely positioned at the intersection of advanced artificial intelligence (AI) capabilities and healthcare, today announced it has been named to Fast Company’s prestigious annual list of the

Pfizer and Eli Lilly's chronic low back pain (CLBP) treatment meets primary endpoint in Phase 3 trial

US firms Pfizer and Eli Lilly have said that NGF inhibitor tanezumab met its primary endpoint in a phase 3 trial of patients with moderate to severe chronic low back pain (CLBP). Treatment with 10mg of tanezumab significantly improved pain at 16 weeks when compared to placebo. An estimated 33 million Americans suffer from CLBP, eight million of whom suffer from a moderate-to-severe form of the con...

Mogrify Raises $3.7 Million USD Seed Funding to Accelerate Its Mission to Transform Cell Therapy via Direct Cellular Conversion

Darrin M Disley, PhD, DSc, OBE, appointed as CEO New investment from Ahren Innovation Capital, 24Haymarket and Dr Disley Mogrify’s technology enables the conversion of any mature cell type into any other mature cell type without going through a pluripotent stem cell- or progenitor cell-state ...

Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic

Tolerability: AZD8601 was well tolerated when administered directly into the skin Protein Expression: Demonstrated dose-dependent protein translation Protein Pharmacology: mRNA injected directly into skin of patients showed evidence of increased blood flow AZD8601 now in an ongoing Phase 2a study with patients receiving ep...

Keytruda falls short at Phase 3 in advanced liver cancer

MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive care, failed to meet its primary endpoints of overall survival or progression-free survival in the treatment of patients with advanced hepatocellular carcinoma (HCC) who were previously treated with systemic therapy. The company noted that both rates fo...

Acarix Year-End Report 2018: Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market

Malmö, February 20, 2019 Acarix Year-End Report 2018: Market dynamics favourable for CADScor®System, addressing the challenges of the global healthcare market "After six months at Acarix, I clearly see our market evolving and a growing opportunity for our products aimed at revolutionizing cardiac diagnostics. At congresses and scientific events, an increasing number of presentatio...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks